Harout Semerjian is recorded as Board Member at Geron Corp (GERN) since August 7, 2025 and CEO at Geron Corp (GERN). Geron Corp reported in an 8-K filed August 6, 2025 that Harout Semerjian was appointed Class I director, effective August 7, 2025. Geron Corp reported in an 8-K filed August 6, 2025 that Harout Semerjian was appointed President and Chief Executive Officer, effective August 7, 2025. The proxy statement of Geron Corp reports total compensation of $10,221,755 for Harout Semerjian in fiscal 2025, including a base salary of $321,538. Harout Semerjian has spoken on 6 earnings calls and 6 other investor events across 1 company, most recently for Geron Corp on November 10, 2026. Geron Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Geron Corp includes Elizabeth G. O'Farrell (Chairman and Board Member), Michelle J. Robertson (CFO), Shanthakumar Tyavanagimatt (CTO) and 7 others.
“On the Effective Date, Mr. Semerjian will be appointed to the Board to fill the existing vacancy as a Class I director for a term expiring at the Company’s 2027 annual meeting of stockholders.”
“On August 1, 2025, the Board of Directors (the “Board”) of Geron Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Harout Semerjian as President and Chief Executive Officer of the Company and as a director, effective August 7, 2025 (the “Effective Date”).”
“Yeah, well, thank you, Steve, and thank you to Steve Hall for the opportunity to present our story. Our story continues to emerge as a commercial company. Now, last week, we have reported our fourth quarter of back-to-back growth.”
“We continue to execute our strategy to build a leading hematology company. We're delivering consistent Ritello demand growth, reinforcing our confidence in the low-risk MDS-US commercial opportunity and Ritello's growth trajectory over the next several years.”
“Yeah, thank you, Emily, and thank you for ACO Invite for this opportunity to share our exciting journey at Geron, which has been a few decades in the making.”
“Our second quarter results demonstrate the continued progress we are making and the momentum we are building as we execute our strategy outlined at the beginning of the year.”
“Thank you, Corinne, and thank you for the Goldman Sachs team for the invitation to share why we are excited at GERON. So GERON is now a commercial stage company.”
